FEMASYS INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
FEMY$1.43+0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets at December 31, 2023 and 2022
| Assets | December 31, 2023 | December 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $21,716,077 | 12,961,936 |
| Accounts receivable, net | 98,906 | 77,470 |
| Inventory, net | 667,118 | 436,723 |
| Prepaid and other current assets | 695,879 | 655,362 |
| Total current assets | 23,177,980 | 14,131,491 |
| Property and equipment, at cost: | ||
| Leasehold improvements | 1,212,417 | 1,195,637 |
| Office equipment | 47,308 | 99,344 |
| Furniture and fixtures | 414,303 | 419,303 |
| Machinery and equipment | 2,559,356 | 2,572,243 |
| Construction in progress | 423,077 | 413,843 |
| 4,656,461 | 4,700,370 | |
| Less accumulated depreciation | (3,545,422) | (3,217,319) |
| Net property and equipment | 1,111,039 | 1,483,051 |
| Long-term assets: | ||
| Lease right-of-use assets, net | 2,380,225 | 319,557 |
| Intangible assets, net of accumulated amortization | — | 3,294 |
| Other long-term assets | 1,086,581 | 958,177 |
| Total long-term assets | 3,466,806 | 1,281,028 |
| Total assets | $27,755,825 | 16,895,570 |
(continued)
Balance Sheets
| Liabilities and Stockholders’ Equity | December 31, 2023 | December 31, 2022 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $1,137,823 | 510,758 |
| Accrued expenses | 1,444,296 | 456,714 |
| Note payable | — | 141,298 |
| Clinical holdback – current portion | 65,300 | 45,206 |
| Lease liabilities – current portion | 406,636 | 373,833 |
| Total current liabilities | 3,054,055 | 1,527,809 |
| Long-term liabilities: | ||
| Clinical holdback – long-term portion | 54,935 | 96,658 |
| Convertible notes payable, net (including related parties) | 4,258,179 | — |
| Lease liabilities – long-term portion | 2,036,067 | 28,584 |
| Total long-term liabilities | 6,349,181 | 125,242 |
| Total liabilities | 9,403,236 | 1,653,051 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par, 200,000,000 authorized, 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023; and 11,986,927 shares issued and 11,869,704 outstanding as of December 31, 2022 | 21,775 | 11,987 |
| Treasury stock, 117,223 common shares | (60,000) | (60,000) |
| Warrants | 2,787,137 | 567,972 |
| Additional paid-in-capital | 123,985,306 | 108,857,065 |
| Accumulated deficit | (108,381,629) | (94,134,505) |
| Total stockholders’ equity | 18,352,589 | 15,242,519 |
| Total liabilities and stockholders’ equity | $27,755,825 | 16,895,570 |
Statements ofComprehensive Loss
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.